Could a simple pill combo stop deadly rebleeds in cirrhosis?

NCT ID NCT07465471

Not yet recruiting Disease control Sponsor: Institute of Liver and Biliary Sciences, India Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding midodrine to the standard drug carvedilol can prevent early rebleeding in people with cirrhosis who have had a variceal bleed. About 210 high-risk patients will receive either carvedilol alone or carvedilol plus midodrine for 6 weeks. The goal is to see if the combination reduces the chance of another bleed and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carvedilol and midodrine
What this could lead to: If it works, this could offer a simple, oral drug combination to reduce dangerous early rebleeding in cirrhosis patients, potentially improving survival without needing complex procedures.
What could go wrong: This is a small, early-stage trial (210 people) that hasn't started recruiting yet. The benefit may be modest, and side effects like low blood pressure or slow heart rate could limit use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS

Contacts and locations

Locations

Institute of Liver and Biliary Sciences

New Delhi, National Capital Territory of Delhi, 110070, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.